Apps in this category may contain mild or occasional cartoon, fantasy or real-life violence, as well as occasional or mild adult, sexually suggestive or horrifying content and may not be suitable for children under 9 years of age.

12+

Apps in this category may contain occasional mild indecent language, frequent or intense cartoon or real-life violence, minor or occasional adult or sexually suggestive material, and simulated gambling, and may be for children under 12 years of age.

17+

You must be at least 17 years old to access this App.

Apps in this category may contain frequent and intense offensive language; Frequent and intense cartoon, fantasy or realistic violence: frequent and intense adult, scary and sexually suggestive subjects: as well as sexual content, nudity, tobacco, alcohol and drugs, may not be suitable for children under 17 years of age.

لقطات الشاشة لـ SARCULATOR

iPad

iPhone

About SARCULATOR

This app is meant to be used only by physicians and it is not meant to make clinical decisions (the clinical usefulness of the two models has not been tested) but to be used as an informative tool to improve the predictive capability of a physician.

Two kinds of predictions are possible:

- RPS: 5-year overall survival (OS) and 5-year disease-free survival (DFS) in primary resected retroperitoneal sarcoma (RPS) patients. .
- STS: 5- and 10-year overall survival (OS) and cumulative incidence of distant metastasis (CCI of DM) in primary resected extremity STS patients.

تحديث لأحدث إصدار 2.2.1

Last updated on 06/11/2023

الإصدارات القديمة

Update: new model for patients with primary RPS taking into consideration the improved outcome over time and the case-volume effect.

Version History

2.2.1

06/11/2023

Update: new model for patients with primary RPS taking into consideration the improved outcome over time and the case-volume effect.

2.2

31/10/2023

Update: new model for patients with primary RPS taking into consideration the improved outcome over time and the case-volume effect.

Aggiornamento: nuovo modello per pazienti con sarcomi primitivi del retroperitoneo che tiene in considerazione del miglioramento della prognosi osservata negli anni recenti e l’effetto del volume del centro.

2.1.2

28/07/2022

Improved interface. New dynamic nomogram to predict prognosis during follow-up in retroperitoneal sarcoma survivors.

2.1.1

27/07/2022

Improved interface. New dynamic nomogram to predict prognosis during follow-up in retroperitoneal sarcoma survivors.

2.1

25/07/2022

Improved interface. New dynamic nomogram to predict prognosis during follow-up in retroperitoneal sarcoma survivors.

2.0

13/11/2019

Support for iOS 13